5-chloro-3-(3,4,5-trimethoxybenzyliden)indolin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-3-(3,4,5-trimethoxybenzyliden)indolin-2-one
• 英文别名: BSc3925；(Z)-5-chloro-3-(3,4,5-trimethoxy-benzylidene)-1,3-dihydro-indol-2-one；(3Z)-5-Chloro-3-[(3,4,5-trimethoxyphenyl)methylidene]-2,3-dihydro-1H-indol-2-one；(3Z)-5-chloro-3-[(3,4,5-trimethoxyphenyl)methylidene]-1H-indol-2-one
• 化学式: C₁₈H₁₆ClNO₄
• 分子量: 345.782
• InChiKey: UBHPXDOWPCUKCB-MLPAPPSSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-chloro-3-(3,4,5-trimethoxybenzyliden)indolin-2-one 以 甲醇 为溶剂， 反应 48.0h， 生成 (E)-5-chloro-3-(3,4,5-trimethoxybenzylidene)indolin-2-one
  参考文献：
  名称：

  Inhibition of γ-secretase by the CK1 inhibitor IC261 does not depend on CK1δ

  摘要：

  CK1 and gamma-secretase are interesting targets for therapeutic intervention in the treatment of cancer and Alzheimer's disease. The CK1 inhibitor IC261 was reported to inhibit gamma-secretase activity. The question is: Does CK1 inhibition directly influence gamma-secretase activity? Therefore we analyzed the SAR of 15 analogues and their impact on gamma-secretase activity. The most active compounds were investigated on CK1 delta activity. These findings exclude a direct influence of CK1 delta on gamma-secretase, because any change in the substitution pattern of IC261 diminished CK1 inhibition, whereas gamma-secretase inhibition is still exerted by several analogues. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.110

文献信息

• [EN] NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES<br/>[FR] NOUVELLE UTILISATION THERAPEUTIQUE DE DERIVES D'INDOLINONE
  申请人：LEO PHARMA AS

  公开号：WO2005058309A1

  公开（公告）日：2005-06-30

  Certain oxindole compounds have been found to be effective in experimentally induced autoimmune encephalitis and are therefore suggested for the preparation of a medicament for the prevention, treatment or amelioration of multiple sclerosis, or to delay the onset of or reduce the relapse rate in multiple sclerosis.

  某些氧吲哚化合物已被发现在实验诱导的自身免疫性脑炎中具有有效性，因此建议用于制备用于预防、治疗或改善多发性硬化症的药物，或延缓多发性硬化症的发作或减少复发率。
• Novel therapeutic use
  申请人：Bouerat Duvold Maud Elysa Laetitia

  公开号：US20070167488A1

  公开（公告）日：2007-07-19

  Certain oxindole compounds have been found to be effective in experimentally induced autoimmune encephalitis and are therefore suggested for the preparation of a medicament for the prevention, treatment or amelioration of multiple sclerosis, or to delay the onset of or reduce the relapse rate in multiple sclerosis.

  某些恶唑酮化合物已被发现在实验性自身免疫脑炎中具有疗效，因此建议用于制备用于预防、治疗或改善多发性硬化症的药物，或者延迟多发性硬化症的发作或减少复发率。
• NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES
  申请人：LEO PHARMA A/S

  公开号：EP1696906A1

  公开（公告）日：2006-09-06
• USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS
  申请人：D'Mello Santosh R.

  公开号：US20100298376A1

  公开（公告）日：2010-11-25

  The present invention provides compositions and methods of synthesizing optionally substituted 3-substituted indolin-2-ones and methods to employ the resultant compounds to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such as ischemic stroke.
• Inhibition of γ-secretase by the CK1 inhibitor IC261 does not depend on CK1δ
  作者：Nicole Höttecke、Miriam Liebeck、Karlheinz Baumann、Robert Schubenel、Edith Winkler、Harald Steiner、Boris Schmidt

  DOI：10.1016/j.bmcl.2010.02.110

  日期：2010.5

  CK1 and gamma-secretase are interesting targets for therapeutic intervention in the treatment of cancer and Alzheimer's disease. The CK1 inhibitor IC261 was reported to inhibit gamma-secretase activity. The question is: Does CK1 inhibition directly influence gamma-secretase activity? Therefore we analyzed the SAR of 15 analogues and their impact on gamma-secretase activity. The most active compounds were investigated on CK1 delta activity. These findings exclude a direct influence of CK1 delta on gamma-secretase, because any change in the substitution pattern of IC261 diminished CK1 inhibition, whereas gamma-secretase inhibition is still exerted by several analogues. (C) 2010 Elsevier Ltd. All rights reserved.